Patents by Inventor J. Vaughan

J. Vaughan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120258114
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 11, 2012
    Inventors: JOCHEN G. SALFELD, DEBORAH J. ALLEN, HENDRICUS R.J.M. HOOGENBOOM, ZEHRA KAYMACALAN, BORIS LABKOVSKY, JOHN A. MANKOVICH, BRIAN T. MCGUINNESS, ANDREW J. ROBERTS, PAUL SAKORAFAS, DAVID SCHOENHAUT, TRISTAN J. VAUGHAN, MICHAEL WHITE, ALISON J. WILTON
  • Publication number: 20120219564
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 30, 2012
    Applicant: ABBOTT BIOTECHNOLOGY LTD.
    Inventors: JOCHEN G. SALFELD, DEBORAH J. ALLEN, HENDRICUS R.J.M. HOOGENBOOM, ZEHRA KAYMAKCALAN, BORIS LABKOVSKY, JOHN A. MANKOVICH, BRIAN T. MCGUINNESS, ANDREW J. ROBERTS, PAUL SAKORAFAS, DAVID SCHOENHAUT, TRISTAN J. VAUGHAN, MICHAEL WHITE, ALISON J. WILTON
  • Publication number: 20120178107
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: December 30, 2011
    Publication date: July 12, 2012
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R.J.M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Patent number: 8206714
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: June 26, 2012
    Assignee: Abbott Biotechnology Ltd.
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R. J. M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Patent number: 8197813
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: June 12, 2012
    Assignee: Abbott Biotechnology Ltd.
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Publication number: 20100040604
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: October 13, 2009
    Publication date: February 18, 2010
    Inventors: Jochen G. SALFELD, Deborah J. Allen, Hendricus R.J.M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Publication number: 20100016557
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: March 10, 2009
    Publication date: January 21, 2010
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R.J.M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Patent number: 7588761
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: September 15, 2009
    Assignee: Abbott Biotechnology Ltd.
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Publication number: 20090155205
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Application
    Filed: February 11, 2009
    Publication date: June 18, 2009
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R.J.M Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Patent number: 7541031
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: June 2, 2009
    Assignee: Abbott Biotechnology Ltd.
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, Hendricus R. J. M. Hoogenboom, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Publication number: 20080129298
    Abstract: This document discloses, among other things, multi-channel magnetic resonance using a TEM coil.
    Type: Application
    Filed: February 17, 2007
    Publication date: June 5, 2008
    Inventors: J. Vaughan, Pierre-Francois Moortele, Lance DelaBarre, Christopher Olson, Heather Orser, Anand Gopinath, Kamil Ugurbil, Carl Snyder, Gregor Adriany, Can Akgun, Jinfeng Tian, John Strupp, Peter Andersen, Xiaoping Wu
  • Publication number: 20080088305
    Abstract: Technology for controlling non-uniformity in the B1 field includes selecting the phase, magnitude, frequency, time, or spatial relationship among various elements of a multi-channel excitation coil in order to control the radio frequency (RF) power emanating from the coil antenna elements. Non-uniformity can be used to steer a constructively interfering B1 field node to spatially correlate with an anatomic region of interest. A convex (quadratically constrained quadratic problem) formulation of the B1 localization problem can be used to select parameters for exciting the coil. Localization can be used in simulated Finite Difference Time Domain B1 field human head distributions and human head phantom measurement.
    Type: Application
    Filed: May 3, 2007
    Publication date: April 17, 2008
    Inventors: Christopher Olson, J. Vaughan, Anand Gopinath
  • Publication number: 20080084210
    Abstract: A current unit having two or more current paths allows control of magnitude, phase, time, frequency and position of each of element in a radio frequency coil. For each current element, the current can be adjusted as to a phase angle, frequency and magnitude. Multiple current paths of a current unit can be used for targeting multiple spatial domains or strategic combinations of the fields generated/detected by combination of elements for targeting a single domain in magnitude, phase, time, space and frequency.
    Type: Application
    Filed: September 20, 2007
    Publication date: April 10, 2008
    Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: J. Vaughan, Gregor Adriany, Carl Snyder, Can Akgun, Jinfeng Tian, Kamil Ugurbil, Pierre-Francois Van de Moortele, Steen Moeller
  • Publication number: 20070290688
    Abstract: An RF coil suitable for use in imaging systems is provided which coil has a dielectric filled cavity formed by a surrounding conducting enclosure, the conducting enclosure preferably being patterned to form continuous electrical paths around the cavity, each of which paths may be tuned to a selected resonant frequency. The patterning breaks up any currents induced in the coil and shortens path lengths to permit higher frequency, and thus higher field strength operation. The invention also includes improved mechanisms for tuning the resonant frequency of the paths, for selectively detuning the paths, for applying signal to the coil, for shortening the length of the coil and for controlling the field profile of the coil and the delivery of field to the object to the image.
    Type: Application
    Filed: August 31, 2007
    Publication date: December 20, 2007
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventor: J. Vaughan
  • Publication number: 20070289028
    Abstract: A computer readable media containing instructions for a processor to implement a plurality of steps comprising: accessing a time constraint for an entitlement, determining whether the time constraint has been satisfied, and responsive to the determination that the time constraint has been satisfied, modifying the entitlement, wherein the duration of the entitlement is less than the duration of the license for the digital content.
    Type: Application
    Filed: June 27, 2006
    Publication date: December 13, 2007
    Applicant: Software Spectrum, Inc.
    Inventors: Michael J. Vaughan, Erich K. Jacobs, Craig S. Brusseau, Norman J. Dumont, Bruce C. Penney, John M. Covino
  • Publication number: 20070288389
    Abstract: Embodiments relate generally to ensuring version compliance for software products used within an enterprise. Generally, compliance is checked by comparing the number of actual uses of each product version to license information relating to product versions. An enterprise is compliant if use of a product version is covered by a license. License information and actual usage information are generally collected to allow for such a comparison. Information concerning license attributes such as downgrade coverage and/or license type may allow for a more accurate determination of the number of each product version ultimately available. Additionally, a rollup procedure may be used to apply updates to base licenses. Version compliance may be performed as a stand-alone feature, or it may be used in conjunction with an entitlement coordination framework to manage usage throughout the enterprise.
    Type: Application
    Filed: December 29, 2006
    Publication date: December 13, 2007
    Inventors: Michael J. Vaughan, Erich K. Jacobs, Craig S. Brusseau, Norman J. Dumont, Bruce D. Penney, John M. Covino
  • Publication number: 20070247160
    Abstract: An RF coil suitable for use in imaging systems is provided which coil has a dielectric filled cavity formed by a surrounding conducting enclosure, the conducting enclosure preferably being patterned to form continuous electrical paths around the cavity, each of which paths may be tuned to a selected resonant frequency. The patterning breaks up any currents inducted in the coil and shortens path lengths to permit higher frequency, and thus higher field strength operation. The invention also includes improved mechanisms for tuning the resonant frequency of the paths, for selectively detuning the paths, for applying signal to the coil, for shortening the length of the coil and for controlling the field profile of the coil and the delivery of field to the object to the image.
    Type: Application
    Filed: July 3, 2007
    Publication date: October 25, 2007
    Applicant: The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventor: J. Vaughan
  • Patent number: 7223394
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: March 7, 2001
    Date of Patent: May 29, 2007
    Assignee: Abbott Biotechnology Ltd
    Inventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
  • Publication number: 20070108980
    Abstract: This document discusses, among other things, a system and method for a coil having a plurality of resonant elements and an adjustable frame. A position of at least one resonant element can be adjusted relative to at least one other resonant element. A variable impedance is coupled to adjacent resonant elements and the impedance varies as a function of a separation distance. Cables are coupled to each resonant element and are gathered at a junction in a particular manner.
    Type: Application
    Filed: November 14, 2006
    Publication date: May 17, 2007
    Inventors: Gregor Adriany, Pierre-Francois Van de Moortele, Johannes Ritter, William Voje, J. Vaughan, Kamil Ugurbil
  • Publication number: 20070007964
    Abstract: An RF coil suitable for use in imaging systems is provided which coil has a dielectric filled cavity formed by a surrounding conducting enclosure, the conducting enclosure preferably being patterned to form continuous electrical paths around the cavity, each of which paths may be tuned to a selected resonant frequency. The patterning breaks up any currents inducted in the coil and shortens path lengths to permit higher frequency, and thus higher field strength operation. The invention also includes improved mechanisms for tuning the resonant frequency of the paths, for selectively detuning the paths, for applying signal to the coil, for shortening the length of the coil and for controlling the field profile of the coil and the delivery of field to the object to the image.
    Type: Application
    Filed: September 15, 2006
    Publication date: January 11, 2007
    Inventor: J. Vaughan